Gut commensal Kineothrix alysoides mitigates liver dysfunction by restoring lipid metabolism and gut microbial balance
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as Non-Alcoholic Fatty Liver Disease, is a widespread liver condition characterized by excessive fat buildup in hepatocytes without significant alcohol consumption. Manipulation of the gut microbiome has been consider...
Gespeichert in:
Veröffentlicht in: | Scientific reports 2023-09, Vol.13 (1), p.14668-14668, Article 14668 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as Non-Alcoholic Fatty Liver Disease, is a widespread liver condition characterized by excessive fat buildup in hepatocytes without significant alcohol consumption. Manipulation of the gut microbiome has been considered to prevent and improve the occurrence and progression of MASLD, particularly through the gut-liver axis. This study aimed to investigate the correlation between the gut microbiome and liver function and determine whether the gut microbiome can ameliorate MASLD. We comparatively analyzed the gut microbiome composition between mice fed normal chow and those fed a high-fat diet and observed that the abundance of
Kineothrix alysoides
decreased in the high-fat group. Further analysis showed that treatment with
K. alysoides
in the high-fat diet group led to decreased weight loss, and MASLD attenuation. Importantly,
K. alysoides
treatment attenuated MASLD in mice fed a high-fat, high-fructose diet (HFHF), which can cause advanced liver damage. Furthermore, administration of
K. alysoides
altered the gut microbial composition in the HFHF diet group and improved MASLD. Overall, these findings demonstrate the potential of
K. alysoides
in restoring gut health and facilitating lipid metabolism to prevent and treat MASLD. |
---|---|
ISSN: | 2045-2322 2045-2322 |
DOI: | 10.1038/s41598-023-41160-y |